New scan could sharpen view of head and neck cancers
NCT ID NCT05183048
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether a special tracer called 89Zr panitumumab, used with PET/MRI scans, can show head and neck tumors more clearly than the standard FDG tracer. Fourteen newly diagnosed patients scheduled for surgery will receive both scans. The results are for research only and will not change their treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- [89Zr]Panitumumab Tracer
- What this could lead to
- If successful, this could lead to a more accurate imaging method for head and neck cancers, helping surgeons plan better.
- What could go wrong
- This is a very early, small study (14 people) focused only on imaging, not treatment. The new tracer may not prove better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 14 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2023
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck 2. Subjects newly diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. 3. Subjects are to be staged clinically and radiographically node negative (cN0) 4. Planned standard of care surgery with curative intent for squamous cell carcinoma 5. Age \> 18 years 6. Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results: 1. Hemoglobin ≥ 9 gm/dL 2. White blood cell count ≥ 3000/mm3 3. Platelet count ≥ 100,000/mm3 4. Serum creatinine ≤ 1.5 times upper reference range 5. alanine transaminase (ALT) (SGPT) 7-56 units/liter, aspartate aminotransferase (AST) (SGOT) 5-40 units/liter. Exclusion Criteria: 1. Received an investigational drug within 30 days prior to the first dose of \[89Zr\]panitumumab. 2. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. 3. Previous HNSCC resection. 4. History of infusion reactions to monoclonal antibody therapies. 5. Pregnant or breast-feeding women. 6. Magnesium (\<1.7 mg/dL) or potassium (\<3.6 mmol/L) lower than the normal institutional values. 7. Subjects receiving Class I-A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. 8. Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. 9. Severe renal disease or anuria (Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels). 10. Known hypersensitivity to panitumumab or any of its components. 11. Weight over 350 lbs., due to the scanner bore size. 12. Contraindication for MRI procedures (e.g. non-removable metal implants or certain tattoos).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UAB
RECRUITINGBirmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer aims to light up hidden cancer targets
- Can immunotherapy before surgery stop early oral cancer from returning?
- Can a glowing dye show surgeons where head and neck tumors end?
- Can a Four-Part combo before surgery wipe out head and neck tumors?
- Can a new drug shrink advanced solid tumors?
- Can steroid shots shield salivary glands from radiation damage?